DOCSLIB.ORG

PCF Updated Website Monographs (Since PCF5 Publication) November 2014 to September 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PCF Updated Website Monographs (Since PCF5 Publication) November 2014 to September 2017 www.palliativedrugs.com PCF updated website monographs (since PCF5 publication) November 2014 to September 2017 Monograph Chapter number Date updated Oral nutritional supplements Chapter 29 Correction Nov-14 Antihistaminic antimuscarinic anti-emetics Chapter 04 Minor change Feb-15 QCG: Vertigo Chapter 04 New Feb-15 Urinary tract infections Chapter 06 Minor change Feb-15 Corticosteroids (systemic) Chapter 07 Minor change Apr-15 Prolongation of the QT interval in palliative care Chapter 24 Minor change Apr-15 Propofol Chapter 13 Minor change Apr-15 Strong opioids Chapter 05 Apr-15 Antacids Chapter 01 May-15 Compound alginate products Chapter 01 May-15 Drugs and fitness to drive Chapter 19 May-15 Oral nutritional supplements Chapter 29 May-15 Products for haemorrhoids Chapter 01 May-15 Simeticone Chapter 01 May-15 Variability in response to drugs Chapter 25 May-15 Zinc Chapter 09 May-15 Fentanyl (transmucosal) Chapter 05 Jun-15 Ketamine Chapter 13 Jun-15 Ascorbic acid Chapter 09 Jul-15 Catheter Patency solutions Chapter 08 Jul-15 Discoloured urine Chapter 08 Jul-15 Pancreatin Chapter 01 Jul-15 Potassium Chapter 09 Jul-15 Rectal products for constipation Chapter 01 Jul-15 Antimuscarinics Chapter 01 Minor change Aug-15 H2-receptor antagonists Chapter 01 Aug-15 Misoprostol Chapter 01 Discontinued Aug-15 Phenobarbital Chapter 04 Minor change Aug-15 Proton pump inhibitors Chapter 01 Aug-15 Anti-emetics Chapter 04 Minor change Nov-15 Guidance about prescribing in palliative care Chapter 14 Correction Nov-15 Levomepromazine Chapter 04 Minor change Nov-15 Prolongation of the QT interval in palliative care Chapter 24 Minor change Nov-15 Rifampicin Chapter 06 New Nov-15 Benzodiazepines Chapter 04 Correction Jan-16 Cellulitis in a lymphoedematous limb Chapter 06 Jan-16 QCG: Cellulitis in lymphoedema Chapter 06 Jan-16 Opioid dose conversion ratios Chapter 15 Minor change Mar-16 QCG: Use of transdermal buprenorphine patches Chapter 05 Minor change Mar-16 Progestogens Chapter 07 Apr-16 Opioid antagonists Chapter 05 Minor change May-16 Furosemide Chapter 02 Jun-16 Prolongation of the QT interval in palliative care Chapter 24 Minor change Jun-16 Proton pump inhibitors Chapter 01 Minor change Jul-16 Antihistaminic antimuscarinic anti-emetics Chapter 04 Minor change Aug-16 Corticosteroids (systemic) Chapter 07 Minor change Aug-16 Danazol Chapter 07 Aug-16 Demeclocycline Chapter 07 Aug-16 Desmopressin Chapter 07 Aug-16 H2-receptor antagonists Chapter 01 Minor change Aug-16 Haemostatics Chapter 02 Aug-16 Helicobacter pylori gastritis Chapter 06 Discontinued Aug-16 Laxatives Chapter 01 Minor change Aug-16 Morphine Chapter 05 Minor change Aug-16 www.palliativedrugs.com September 2017 www.palliativedrugs.com PCF updated website monographs continued Monograph Chapter number Date updated Paracetamol Chapter 05 Aug-16 Propofol Chapter 13 Aug-16 QCG: Death rattle (noisy rattling breathing) Chapter 01 Aug-16 QCG: Opioid-induced constipation Chapter 01 Aug-16 Skeletal muscle relaxants Chapter 10 Minor change Aug-16 Anti-emetics Chapter 04 Minor change Sep-16 Systemic local anaesthetics Chapter 02 Nov-16 Antibacterials Chapter 06 Feb-17 Cardiovascular Introduction Chapter 02 Feb-17 Opioid antagonists Chapter 05 Discontinued Feb-17 Opioid antagonists (outside CNS) Chapter 05 New Feb-17 Opioid antagonists (within CNS) Chapter 05 New Feb-17 Spironolactone Chapter 02 Feb-17 Anaphylaxis Appendix 01 (new) Mar-17 Anticipatory prescribing Chapter 15 (new) Mar-17 Drugs and fitness to drive Chapter 22 (new) Mar-17 Obtaining specials Chapter 24 (new) Mar-17 QCG: Respiratory depression Chapter 05 New Mar-17 Taking controlled drugs abroad Chapter 23 (new) Mar-17 Use of medicinal products beyond (off-label) and without a Prelims Mar-17 marketing authorization Baclofen Chapter 10 Apr-17 Cerumenolytics Chapter 11 Apr-17 Clostridium difficile infection Chapter 06 Apr-17 Compatibility charts Appendix 03 Apr-17 Continuous subcutaneous drug infusions Chapter 29 (new) Apr-17 Drug administration to patients with swallowing difficulties Chapter 28 (new) Apr-17 and EFT Drug-induced movement disorders Chapter 21 (new) Apr-17 Drugs for prutitus Chapter 26 (new) Apr-17 Management of post op pain Chapter 25 (new) Apr-17 Mouthwashes Chapter 11 Apr-17 Nebulized drugs Chapter 31 (new) Apr-17 Opioid dose conversion ratios Appendix 02 (new) Apr-17 Oral nutritional supplements Chapter 27 (new) Apr-17 Prescribing for children Chapter 16 (new) Apr-17 Prescribing in palliative care Chapter 14 (new) Apr-17 Prolongation of the QT interval in palliative care Chapter 20 (new) Renumbered only Apr-17 Renal impairment Chapter 17 (new) New Apr-17 Skeletal muscle relaxants Chapter 10 Apr-17 Spinal analgesia Chapter 32 (new) Apr-17 Strong opioids Chapter 05 Minor change Apr-17 Transdermal patches Chapter 30 (new) New Apr-17 Variability in response to drugs Chapter 19 (new) Renumbered only Apr-17 Dantrolene Chapter 10 Jun-17 Pilocarpine Chapter 11 Jun-17 QCG: Death rattle (noisy rattling breathing) Chapter 01 Jun-17 Simeticone Chapter 01 Minor change Jun-17 Tizanidine Chapter 10 Jun-17 Antimuscarinics Chapter 01 Jul-17 Antitussives Chapter 03 Jul-17 Bronchodilators Chapter 03 Jul-17 Demeclocycline Chapter 07 Minor change Jul-17 Drugs for cough Chapter 03 Jul-17 Glycopyrronium Chapter 01 Jul-17 www.palliativedrugs.com September 2017 2 of 5 www.palliativedrugs.com PCF updated website monographs continued Monograph Chapter number Date updated Hepatic impairment Chapter 18 (new) New Jul-17 Hyoscine butylbromide Chapter 01 Jul-17 Hyoscine hydrobromide Chapter 01 Jul-17 Inhaled long-acting beta2 agonsits (LABAs) Chapter 03 Jul-17 Ipratropium Chapter 03 Jul-17 Ispaghula (psyllium) husk Chapter 01 Jul-17 Loperamide Chapter 01 Jul-17 Mucolytics Chapter 03 Jul-17 Oral candidosis Chapter 06 Jul-17 Orphenadrine Chapter 01 Jul-17 Oxygen Chapter 03 Jul-17 Propantheline Chapter 01 Jul-17 Salbutamol Chapter 03 Jul-17 Skeletal muscle relaxants Chapter 10 Minor change Jul-17 Theophylline Chapter 03 Jul-17 Tiotropium Chapter 03 Jul-17 Anticoagulants Chapter 02 Aug-17 Benzodiazepines and Z-drugs Chapter 04 Aug-17 Clonazepam Chapter 04 Discontinued Aug-17 Clonidine Chapter 02 Aug-17 Depot corticosteroids Chapter 10 Minor change Aug-17 Desmopressin Chapter 07 Aug-17 Diazepam Chapter 04 Discontinued Aug-17 Docusate sodium Chapter 01 Aug-17 Glyceryl trinitrate Chapter 02 Aug-17 Inhaled corticosteroids Chapter 03 Aug-17 Ketamine Chapter 13 Aug-17 Lactulose Chapter 01 Aug-17 Laxatives Chapter 01 Aug-17 LMWH Chapter 02 Aug-17 Lorazepam Chapter 04 Discontinued Aug-17 Macrogols Chapter 01 Aug-17 Magnesium salts Chapter 01 Aug-17 Melatonin Chapter 04 Aug-17 Methenamine hippurate Chapter 08 Minor change Aug-17 Metronidazole Chapter 06 Aug-17 Midazolam Chapter 04 Discontinued Aug-17 Nifedipine Chapter 02 Aug-17 Opioid dose conversion ratios Appendix 02 (new) Minor change Aug-17 Oxybutynin Chapter 08 Aug-17 Phytomenadione Chapter 09 Minor change Aug-17 Prokinetics Chapter 01 Aug-17 Psychotropics Chapter 04 Discontinued Aug-17 QCG: Bowel management in paraplegia and tetraplegia Chapter 01 Aug-17 QCG: Heparin-induced thrombocytopenia Chapter 02 Aug-17 QCG: Opioid-induced constipation Chapter 01 Aug-17 Rectal products for constipation Chapter 01 Aug-17 Stimulant laxatives Chapter 01 Aug-17 Tamsulosin Chapter 08 Minor change Aug-17 Urinary tract infections Chapter 06 Aug-17 5HT3 antagonists Chapter 04 Sep-17 Abbreviations Home page Sep-17 Adjuvant analgesics Chapter 05 Sep-17 Alfentanil Chapter 05 Sep-17 www.palliativedrugs.com September 2017 3 of 5 www.palliativedrugs.com PCF updated website monographs continued Monograph Chapter number Date updated Amitriptyline Chapter 04 Sep-17 Anaemia Chapter 09 Sep-17 Antidepressants Chapter 04 Sep-17 Anti-emetics Chapter 04 Sep-17 Anti-epileptics Chapter 04 Sep-17 Antihistaminic antimuscarinic anti-emetics Chapter 04 Sep-17 Artificial saliva Chapter 11 Sep-17 Barrier products Chapter 12 Sep-17 Bisphosphonates Chapter 07 Sep-17 Buprenorphine Chapter 05 Sep-17 Cannabinoids Chapter 04 Sep-17 Carbamazepine Chapter 04 Sep-17 Celecoxib Chapter 05 Sep-17 Codeine Chapter 05 Sep-17 Cranberry juice Chapter 08 Discontinued Sep-17 Diamorphine Chapter 05 Sep-17 Diclofenac Chapter 05 Sep-17 Dihydrocodeine Chapter 05 Sep-17 Domperidone Chapter 04 Sep-17 Drug names Home page Sep-17 Drugs for diabetes mellitus Chapter 07 Sep-17 Drugs for oral inflammation and ulceration Chapter 11 Sep-17 Drugs for pruritus Chapter 26 (new) Minor change Sep-17 Duloxetine Chapter 04 Sep-17 Emollients Chapter 12 Sep-17 Fentanyl Chapter 05 Sep-17 Fentanyl (transmucosal) Chapter 05 Sep-17 Ferrous sulfate Chapter 09 Sep-17 Flurbiprofen Chapter 05 Sep-17 Gabapentin and pregabalin Chapter 04 Sep-17 Getting the most out of PCF Prelims Sep-17 Haloperidol Chapter 04 Sep-17 How PCF is constructed Prelims Sep-17 Hydromorphone Chapter 05 Sep-17 Ibuprofen Chapter 05 Sep-17 Ketorolac Chapter 05 Sep-17 Levetiracetam Chapter 04 Sep-17 Levomepromazine Chapter 04 Sep-17 Magnesium Chapter 09 Sep-17 Methadone Chapter 05 Sep-17 Metolcopramide Chapter 04 Sep-17 Mirtazapine Chapter 04 Sep-17 Monographs available elsewhere Prelims Discontinued Sep-17 Morphine Chapter 05 Sep-17 Nabumetone Chapter 05 Sep-17 Naproxen Chapter 05 Sep-17 Nefopam Chapter 05 Sep-17 Nortriptyline Chapter 04 Discontinued Sep-17 NSAIDs Chapter 05 Sep-17 Octreotide Chapter 07 Sep-17 Olanzapine Chapter 04 Sep-17 Oxcarbazepine Chapter 04 Sep-17 Paracetamol Chapter 05 Sep-17 Phenobarbital Chapter 04 Sep-17 www.palliativedrugs.com September 2017 4 of 5 www.palliativedrugs.com PCF updated
Load more

Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • Research Article RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs
    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
    [Show full text]
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016
    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
    [Show full text]
  • Marketing Authorisations Granted in December 2020
    Marketing authorisations granted in December 2020 PL Number Grant Date MA Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status Territory PL 14251/0100 01/12/2020 MANX HEALTHCARE LIMITED COLCHICINE 500 MICROGRAMS TABLETS COLCHICINE 0.500 MILLIGRAMS POM UK PL 34424/0050 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 25MG FILM-COATED TABLETS SPIRONOLACTONE 25 MILLIGRAMS POM UK PL 34424/0051 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 50MG FILM-COATED TABLETS SPIRONOLACTONE 50 MILLIGRAMS POM UK PL 34424/0052 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 100MG FILM-COATED TABLETS SPIRONOLACTONE 100 MILLIGRAMS POM UK PL 36282/0021 03/12/2020 RIA GENERICS LIMITED COLCHICINE 500 MICROGRAM TABLETS COLCHICINE 500 MICROGRAMS POM UK PL 39352/0439 03/12/2020 KOSEI PHARMA UK LIMITED FROVATRIPTAN 2.5 MG FILM-COATED TABLETS FROVATRIPTAN SUCCINATE MONOHYDRATE 2.5 MILLIGRAMS POM UK PL 31750/0174 04/12/2020 SUN PHARMACEUTICAL INDUSTRIES EUROPE BV CETRORELIX SUN 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE CETRORELIX ACETATE 0.25 MILLIGRAMS PER MILLILITRE POM UK PL 34424/0054 04/12/2020 KEY PHARMACEUTICALS LIMITED ALIMEMAZINE TARTRATE 10MG FILM COATED TABLETS ALIMEMAZINE TARTRATE 10.00 MILLIGRAMS POM UK PL 17780/0858 07/12/2020 ZENTIVA PHARMA UK LIMITED FINGOLIMOD ZENTIVA 0.5 MG HARD CAPSULES FINGOLIMOD HYDROCHLORIDE 0.56 MILLIGRAMS POM UK PL 01502/0113 08/12/2020 HAMELN PHARMA LTD AMIODARONE HYDROCHLORIDE 20 MG/ML SOLUTION FOR INFUSION AMIODARONE HYDROCHLORIDE 20 MILLIGRAMS POM UK PL 16786/0006 08/12/2020
    [Show full text]
  • Torolac Combined with Oxycodone in Patient- Controlled Analgesia After Gynecol
    Int. J. Med. Sci. 2015, Vol. 12 644 Ivyspring International Publisher International Journal of Medical Sciences 2015; 12(8): 644-649. doi: 10.7150/ijms.11828 Research Paper A Randomized Clinical Trial of Nefopam versus Ke- torolac Combined With Oxycodone in Patient- Controlled Analgesia after Gynecologic Surgery Boo-Young Hwang, Jae-Young Kwon, Do-Won Lee, Eunsoo Kim, Tae-Kyun Kim, Hae-Kyu Kim Department of Anesthesia and Pain Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea Corresponding author: Jae-Young Kwon, Department of Anesthesia and Pain Medicine, Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-793, Republic of Korea. Tel: +82-51-240-7399; Fax: +82-51-242-7466; E-mail: [email protected] © 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. Received: 2015.02.09; Accepted: 2015.07.18; Published: 2015.07.30 Abstract Objectives: Nefopam is a centrally-acting non-opioid analgesic, which has no effect on bleeding time and platelet aggregation. There has been no study about nefopam and oxycodone combina- tion for postoperative analgesia. In this study, we present efficacy and side effects of nefo- pam/oxycodone compared with ketorolac/oxycodone in patient-controlled analgesia (PCA) after gynecologic surgery. Methods: 120 patients undergoing gynecologic surgery were divided randomly into two groups: Nefopam group treated with oxycodone 1 mg and nefopam 1 mg bolus; and Ketorolac group treated with oxycodone 1 mg and ketorolac 1.5 mg bolus.
    [Show full text]
  • ACUPAN Tablets
    Consumer Medicine Information ACUPAN™ Nefopam hydrochloride 30 mg tablets What is in this leaflet This leaflet answers some common questions about ACUPAN tablets. However, it does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. If you have any questions about ACUPAN that are not answered by this leaflet, ask your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ACUPAN against the benefits before prescribing it to you. If you are worried about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with your medicine as you may want to read it again. What ACUPAN is used for The name of your medicine is ACUPAN. ACUPAN belongs to a group of medicines called analgesics, commonly known as pain killers or pain relievers. It contains nefopam hydrochloride as the active ingredient. Nefopam hydrochloride interrupts the pain messages being sent to your brain, and it also acts in your brain to stop pain messages being felt. This means that ACUPAN does not stop the pain from happening, but you will not be able to feel the pain as much. ACUPAN is used to relieve both short term pain and long lasting pain (for example pain after an operation, dental pain, joint or muscle pain or after an injury). ACUPAN should not be used to treat the pain from a heart attack. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed ACUPAN for another purpose.
    [Show full text]
  • New Zealand Data Sheet
    1 PARNATE tranylcypromine film-coated tablets 10 mg New Zealand Data Sheet 1 PARNATE® (10 MG FILM-COATED TABLETS) PARNATE 10 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Parnate 10 mg film-coated tablets: each tablet contains tranylcypromine sulfate equivalent to 10 mg of tranylcypromine. Excipients with known effect: each tablet contains sucrose 6 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Parnate 10 mg film-coated tablets contain "geranium rose" coloured, biconvex, film-coated tablets. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties. 4.2 Dose and method of administration Adults Begin with 20 mg a day given as 10 mg in the morning and 10 mg in the afternoon. If there is no satisfactory response after two weeks, add one more tablet at midday. Continue this dosage for at least a week. A dosage of 3 tablets a day should only be exceeded with caution. When a satisfactory response is established, dosage may be reduced to a maintenance level. Some patients will be maintained on 20 mg per day, some will need only 10 mg daily. If no improvement occurs, continued administration is unlikely to be beneficial. 1 2 PARNATE tranylcypromine film-coated tablets 10 mg When given together with a tranquilliser, the dosage of Parnate is not affected. When the medicine is given concurrently with electroconvulsive therapy, the recommended dosage is 10 mg twice a day during the series and 10 mg a day afterwards as maintenance therapy.
    [Show full text]
  • Clomipramine 25 Mg Capsules, Hard
    Package leaflet: Information for the patient Other medicines and Clomipramine Tell your doctor if you are taking, have recently Clomipramine 10 mg Capsules, Hard taken or might take any other medicines. Clomipramine 25 mg Capsules, Hard Some medicines may increase the side effects of Clomipramine 50 mg Capsules, Hard Clomipramine and may sometimes cause very clomipramine hydrochloride serious reactions. Do not take any other medicines whilst taking Clomipramine without first talking to Read all of this leaflet carefully before you your doctor, especially: start taking this medicine because it contains - medicines for depression, particularly MAOIs (see important information for you. section “Do not take” above) e.g. tranylcypromine, - Keep this leaflet. You may need to read it again. phenelzine, moclobemide; SSRIs e.g. fluoxetine (or - If you have any further questions, ask your have taken within the last 3 weeks), fluvoxamine, doctor or pharmacist. paroxetine, sertraline; SNaRIs e.g. venlafaxine; - This medicine has been prescribed for you only. tricyclic and tetracyclic antidepressants e.g. Do not pass it on to others. It may harm them, amitriptyline, dothiepin, maprotiline even if their signs of illness are the same as yours. - diuretics, also known as ‘water tablets’, e.g. - If you get any side effects, talk to your doctor bendroflumethiazide, furosemide or pharmacist. This includes any possible side - anaesthetics, used for the temporary loss of effects not listed in this leaflet. See section 4. bodily sensation - antihistamines e.g. terfenadine What is in this leaflet - medicines for other mental health conditions 1. What Clomipramine is and what it is used for. such as schizophrenia or manic depression 2.
    [Show full text]
  • 3.2.3 Potential Interaction Between Nefopam and Tramadol
    Potential interaction between nefopam and tramadol CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3 July 2018 Agenda item 3.2.3 Title Potential interaction between nefopam and tramadol Medsafe Submitted by Paper type For advice Pharmacovigilance Team Active constituent Medicines Sponsors Nefopam Acupan tablet 30 mg iNova Pharmaceuticals NZ Ltd Tramadol Arrow – Tramadol capsule 50 mg Teva Pharma NZ Ltd Durotram XR modified release tablet iNova Pharmaceuticals NZ Ltd 100, 200, 300 mg Tramal capsule 50 mg, solution for Seqirus NZ Ltd injection 50 mg/ml, 100 mg/2ml, oral drops 100 mg/ml Tramal SR modified release tablet 50, 100, 150, 200 mg Funding Acupan 30 mg, Arrow-Tramadol 50 mg, Tramal SR 100, 150 and 200 mg Previous MARC The potential interaction between these two medicines has not been meetings discussed previously. Prescriber Update www.medsafe.govt.nz/profs/PUArticles/Sep2015/InteractionsSerotoninSyndrome.htm Schedule Prescription medicine Usage data See section 2.3 Advice sought The Committee is asked to advise whether: The data sheets should be updated regarding the risk of serotonin syndrome if nefopam and tramadol are used in combination or The data sheet for nefopam should be updated with the general risk of serotonin syndrome if used concomitantly with other medicines that increase serotonin levels. This topic requires further communication other than MARC’s Remarks in Prescriber Update. Medicines Adverse Reactions Committee: 3 July 2018 Page 1 of 11 Potential interaction between nefopam and tramadol CONFIDENTIAL
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Nefopam Hydrochloride 30 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 30 mg nefopam hydrochloride. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet White to off-white, circular shaped, biconvex, film coated tablets, debossed with ‘NT’ on one face and plain on other face, approximately 7.00 mm in diameter. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Nefopam Hydrochloride is indicated for the relief of acute and chronic pain, including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 4.2 Posology and method of administration Posology Adults: Dosage may range from 1 to 3 tablets three times daily depending on response. The recommended starting dosage is 1-2 tablets three times daily. Elderly: Older patients may require reduced dosage due to slower metabolism. It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to; in particular, the CNS side effects of Nefopam Hydrochloride and some cases of hallucinations and confusion have been reported in this age group. Paediatric population: The safety and efficacy of Nefopam Hydrochloride in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years. Renal impairment: Patients with end stage renal disease might experience increased serum peak concentrations during treatment with nefopam. In order to avoid that, it is recommended the daily dose should be reduced.
    [Show full text]
  • West Essex CCG Anticholinergic Side-Effects and Prescribing Guidance
    Anticholinergic side-effects and prescribing guidance . Anticholinergic (antimuscarinic) medications: associated with increased risks of impaired cognition and falls in patients over the age of 65 years. Recent research also points to a link to mortality increasing with the number and potency of anticholinergic agents prescribed. Anticholinergic Syndrome: is a state of confusion with characteristic features related to dysfunction of the autonomic parasympathetic (cholinergic) nervous system. Symptoms classified into systemic and CNS manifestations: o Systemic (peripheral) symptoms: Blurred vision, photophobia, non-reactive mydriasis, loss of accommodation response, flushed and dry skin, dry mouth, tachycardia, hypertension and fever. Gastrointestinal and urinary motility are frequently reduced o CNS symptoms: Delirium, agitation, disorientation, and visual hallucinations. Ataxia, choreoathetosis, myoclonus and seizures may also occur without peripheral symptoms. Medication Issues: several commonly prescribed medications that may not be thought of as anticholinergic have significant anticholinergic effects, which when taken with known anticholinergic medication can increase the risk of adverse effects. Many medication groups e.g. antihistamines, tricyclic antidepressants, drugs for asthma and COPD, cold preparations, hyoscine have varying degrees of anticholinergic activity and have the potential to cause Anticholinergic Syndrome . Clinicians should be aware of the risk for chronic anticholinergic toxicity and the fact that not all the symptoms may manifest in patients and if they do suffer some symptoms they could be wrongly attributed to another diagnosis Evidence . A study of patients over 65 found that 20% of participants who scored four or more had died by the end of the two year study period compared with 7% of patients with a score of zero.
    [Show full text]
  • Tolfenamic Acid and Meloxicam Both Provide an Adequate Degree of Postoperative Analgesia in Dogs Undergoing Ovariohysterectomy
    Veterinarni Medicina, 62, 2017 (06): 333–341 Original Paper doi: 10.17221/143/2016-VETMED Tolfenamic acid and meloxicam both provide an adequate degree of postoperative analgesia in dogs undergoing ovariohysterectomy X.Y. Hu, L. Luan, W. Guan, J. Shi, Y.B. Zhao, H.G. Fan* Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China *Corresponding author: [email protected] ABSTRACT: This study was aimed at comparing the postoperative analgesic effects of tolfenamic acid and meloxi- cam in dogs undergoing ovariohysterectomy. Ovariohysterectomy was performed in 24 female dogs. All dogs were administered pre-anaesthetic medication comprised of 0.02 mg/kg i.m. acepromazine, and general anaesthesia was induced with i.v. propofol (4–6 mg/kg) and maintained with 1.5–2.0% isoflurane. Dogs were divided into three groups (n = 8). Following induction of anaesthesia, group C received 0.05 ml/kg sterile saline i.m.; group T received 4 mg/kg tolfenamic acid i.m.; group M received 0.2 mg/kg meloxicam s.c. Heart rate, respiratory rate, rectal tem- perature, mean arterial pressure and arterial oxygen saturation of haemoglobin were monitored intraoperatively. Pain was assessed using the short form of the Glasgow composite pain scale (SF-GCPS) by two observers who were blinded to the treatment groups; pain was assessed at the time of pre-medication (baseline), and at 2, 4, 6, 8, 12 and 24 h after extubation. Rescue analgesia (0.2 mg/kg i.m. methadone) was administered to any dog with an SF-GCPS score of greater than or equal to six during postoperative monitoring.
    [Show full text]